Implementation of the new S2e guideline “first-trimester diagnostics and therapy @ 11–13 + 6 weeks of pregnancy”: a survey in outpatient practices
Janus Willem Schipper(Hannover Re (Germany)), Lars Brodowski(Medizinische Hochschule Hannover), V. Dütemeyer(Medizinische Hochschule Hannover), Andrea Treier(Medizinische Hochschule Hannover), A-L Biermann(Medizinische Hochschule Hannover), R Menkhaus(Johannes Wesling Klinikum Minden), C. v. Kaisenberg(Medizinische Hochschule Hannover), P. Hillemanns(Medizinische Hochschule Hannover)
Cited by 0
Related Papers
Multicenter screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation: comparison with <scp>NICE</scp> guidelines and <scp>ACOG</scp> recommendations
|Ultrasound in Obstetrics and Gynecology|2017|363
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia
|American Journal of Obstetrics and Gynecology|2017|166
Prediction of pre‐eclampsia in twin pregnancy by maternal factors and biomarkers at 11–13 weeks' gestation: data from <scp>EVENTS</scp> trial
|Ultrasound in Obstetrics and Gynecology|2020|46
First-Trimester Combined Multimarker Prospective Study for the Detection of Pregnancies at a High Risk of Developing Preeclampsia Using the Fetal Medicine Foundation-Algorithm
|Fetal Diagnosis and Therapy|2017|43
<scp>STATIN</scp> trial: predictive performance of competing‐risks model in screening for pre‐eclampsia at 35–37 weeks' gestation
|Ultrasound in Obstetrics and Gynecology|2021|31